Payment overview · 2025
General Payments
$1,721.97
91 reported records · 17 companies
Healthcare provider profile · identity verified
Jawad Agha, MD
Allopathic & Osteopathic Physicians|Internal Medicine · HAZEL PARK, MI · NPI 1235164872
Verified facts
What the public records show
CMS Open Payments records show Jawad Agha, MD received $1,721.97 in general payments during 2025 across 91 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 21.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Nurtec Odt, Ozempic, Paxlovid, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 136 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $361.57 | 21.0% | 15 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $265.12 | 15.4% | 13 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $199.60 | 11.6% | 18 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $178.86 | 10.4% | 9 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $112.13 | 6.5% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $91.39 | 5.3% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $86.26 | 5.0% | 4 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $79.63 | 4.6% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $77.35 | 4.5% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $77.35 | 4.5% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $53.78 | 3.1% | 3 | 2025 |
| Orexo US, Inc. | Unresolved — no canonical attribution shown | $43.58 | 2.5% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $23.05 | 1.3% | 1 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $23.00 | 1.3% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $17.71 | 1.0% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $16.85 | 1.0% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $14.74 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,721.97 | 91 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $361.57 | 15 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $199.60 | 18 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $199.60 | 18 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $130.23 | 6 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $113.44 | 5 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $94.20 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $92.76 | 5 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $92.76 | 5 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $86.26 | 4 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $79.63 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $65.42 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $60.82 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $46.78 | 3 | 2025 |
Source payment records
|
|||||
| Zubsolv Normalized: zubsolv |
Drug | Orexo US, Inc. | $43.58 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $34.72 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $28.94 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $24.84 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $23.05 | 1 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $23.00 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $20.31 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $19.37 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $17.71 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $16.53 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $16.53 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $14.74 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 136 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 12 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 108 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
42 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
108 | 27 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
136 | 27 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
12 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 271 | 89 |
| Prednisone | Prednisone | 250 | 174 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 230 | 120 |
| Doxycycline Hyclate | Doxycycline Hyclate | 168 | 123 |
| Metformin Hcl | Metformin Hcl | 156 | 45 |
| Amlodipine Besylate | Amlodipine Besylate | 151 | 52 |
| Tizanidine Hcl | Tizanidine Hcl | 146 | 62 |
| Omeprazole | Omeprazole | 140 | 38 |
| Ozempic | Semaglutide | 136 | 27 |
| Lisinopril | Lisinopril | 135 | 45 |
| Gabapentin | Gabapentin | 128 | 37 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 108 | 27 |
| Tramadol Hcl | Tramadol Hcl | 107 | 36 |
| Losartan Potassium | Losartan Potassium | 105 | 41 |
| Jardiance | Empagliflozin | 102 | 35 |
| Fluticasone Propionate | Fluticasone Propionate | 99 | 39 |
| Levothyroxine Sodium | Levothyroxine Sodium | 91 | 25 |
| Tamsulosin Hcl | Tamsulosin Hcl | 91 | 27 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 91 | 42 |
| Diclofenac Sodium | Diclofenac Sodium | 86 | 39 |
| Azithromycin | Azithromycin | 71 | 60 |
| Famotidine | Famotidine | 71 | 31 |
| Metoprolol Succinate | Metoprolol Succinate | 67 | 23 |
| Carvedilol | Carvedilol | 61 | 18 |
| Fluconazole | Fluconazole | 60 | 38 |
| Cefdinir | Cefdinir | 59 | 50 |
| Mounjaro | Tirzepatide | 56 | 11 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 56 | 20 |
| Ondansetron Odt | Ondansetron | 54 | 31 |
| Metoprolol Tartrate | Metoprolol Tartrate | 51 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 50 | 44 |
| Furosemide | Furosemide | 49 | 14 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 47 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 46 | 16 |
| Pregabalin | Pregabalin | 45 | 11 |
| Farxiga | Dapagliflozin Propanediol | 42 | 12 |
| Ketoconazole | Ketoconazole | 42 | 21 |
| Quetiapine Fumarate | Quetiapine Fumarate | 41 | 13 |
| Trulicity | Dulaglutide | 41 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 40 | 16 |
| Methylprednisolone | Methylprednisolone | 40 | 33 |
| Eliquis | Apixaban | 38 | suppressed |
| Meloxicam | Meloxicam | 38 | 17 |
| Montelukast Sodium | Montelukast Sodium | 38 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 36 | 15 |
| Simvastatin | Simvastatin | 36 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 35 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 35 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 35 | 13 |
| Mupirocin | Mupirocin | 35 | 27 |
| Ventolin Hfa | Albuterol Sulfate | 35 | 31 |
| Doxepin Hcl | Doxepin Hcl | 34 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 34 | 15 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 33 | 22 |
| Nortriptyline Hcl | Nortriptyline Hcl | 32 | suppressed |
| Ibuprofen | Ibuprofen | 30 | 19 |
| Nifedipine Er | Nifedipine | 29 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 27 | suppressed |
| Methocarbamol | Methocarbamol | 26 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 25 | suppressed |
| Finasteride | Finasteride | 25 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Linzess | Linaclotide | 25 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 25 | 14 |
| Metronidazole | Metronidazole | 25 | 18 |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 24 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 24 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 24 | suppressed |
| Spironolactone | Spironolactone | 24 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 24 | 14 |
| Vraylar | Cariprazine Hcl | 24 | suppressed |
| Alprazolam | Alprazolam | 23 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Topiramate | Topiramate | 22 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 21 | suppressed |
| Cephalexin | Cephalexin | 20 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 20 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 19 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 19 | 12 |
| Allopurinol | Allopurinol | 18 | suppressed |
| Baclofen | Baclofen | 18 | suppressed |
| Dulera | Mometasone/Formoterol | 18 | suppressed |
| Potassium Chloride | Potassium Chloride | 18 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 18 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 16 | 14 |
| Diazepam | Diazepam | 16 | suppressed |
| Ezetimibe | Ezetimibe | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Methotrexate | Methotrexate Sodium | 16 | suppressed |
| Bupropion Xl | Bupropion Hcl | 15 | suppressed |
| Celecoxib | Celecoxib | 15 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Klor-Con M20 | Potassium Chloride | 15 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Temazepam | Temazepam | 15 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 12 |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Alendronate Sodium | Alendronate Sodium | 11 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Lubiprostone | Lubiprostone | 11 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 11 | suppressed |
| Pramipexole Er | Pramipexole Di-Hcl | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
| Xarelto | Rivaroxaban | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,721.97 · 91 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | AIRSUPRA, APTIMA, ARISTADA, Auvelity, BREZTRI, CAPLYTA, Cologuard Collection Kit, FREESTYLE LIBRE 3, Korlym, LYBALVI, NURTEC ODT, Ozempic, PAXLOVID, QULIPTA, REXULTI, Symbravo, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR, WATCHMAN FLX, Wegovy, ZAVZPRET, ZORYVE, Zubsolv | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Nurtec Odt play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error